Articles Tagged With:
-
FDA Approves New COVID Vaccine for Fall
COVID-19 advisors to the FDA voted unanimously to approve a new monovalent vaccine for the coming fall containing the currently predominant omicron subvariant XBB.1.5.
-
Walk! A Long-Term Observational Investigation of Knee Osteoarthritis
An observational study of more than 1,000 individuals aged 50 years and older with knee arthritis revealed that regular walking for exercise correlates with fewer reports of new knee pain and slower disease progression, as verified by radiographic evidence at eight-year follow-up.
-
Influenza Vaccination May Temporarily Aid Cardiovascular Event Prevention
Researchers studied English patients with an acute cardiovascular event who received an influenza vaccine in the same 12-month period and compared that to the 120-day period after vaccination and the rest of the year. They observed those vaccinated were less likely to experience an acute cardiovascular event for 120 days after vaccine vs. the rest of the year.
-
Using an Online e-Health Program to Improve Postpartum Depression
This study demonstrated that combined use of universal depression screening and MomMoodBooster2, a cognitive behavioral therapy-based e-health program, were effective tools for treating women with depression in the perinatal period.
-
Feds Weigh In on Psychedelic Medicine Clinical Trials
FDA issues draft guidance for researchers studying alternative therapies.
-
Patients with Limited English Proficiency Pose Risks
It is critical for administrators to provide professional interpreter services for all languages commonly spoken among patient populations that present to emergency departments most often.
-
Glycoprotein IIb/IIIa Receptor Inhibitor Tirofiban for Ischemic Stroke
Glycoprotein IIb/IIIa receptor inhibitors are potent, rapidly acting antiplatelet agents that have been tried in pilot studies to treat acute ischemic stroke, without significant benefit. Tirofiban is fast-acting, highly selective, and has a short half-life that allows bleeding time to return to normal within three hours after administration is stopped. The investigators proposed that this medication may be of benefit in patients with acute ischemic stroke who arrived within 24 hours after stroke onset but are not eligible for thrombolysis or thrombectomy or have progression of stroke symptoms after receiving thrombolysis.
-
Endovascular Thrombectomy for Large Ischemic Core Strokes
Endovascular thrombectomy has been rapidly adopted throughout the world for the treatment of patients with acute ischemic stroke and large vessel occlusion. This approach has achieved strong recommendations in stroke guidelines. However, the trials that form the basis of the recommendations have strict imaging recruitment criteria.
-
Is Dexamethasone Effective in the Treatment of Chronic Subdural Hematomas?
Chronic subdural hematomas are common disorders and may occur after minor trauma or no trauma. For decades, nonsurgical therapies have been tried and proposed, including the use of corticosteroids. Various case series and nonrandomized trials of treatment with corticosteroids have been reported to show benefit, but efficacy of steroid therapy has been uncertain.
-
Decompressive Craniectomy for Acute Subdural Hematoma
There has been longstanding discussion about whether craniectomy results in better outcomes than craniotomy with preservation of the skull for treatment of patients with acute subdural hematomas. This multicenter, international clinical trial was designed to compare the long-term results, benefits, and complications of decompressive craniectomy vs. craniotomy in patients with acute subdural hematomas.